ES2133953T3 - Esteres de borneol, procedimiento para su preparacion y su utilizacion farmaceutica. - Google Patents
Esteres de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.Info
- Publication number
- ES2133953T3 ES2133953T3 ES96909153T ES96909153T ES2133953T3 ES 2133953 T3 ES2133953 T3 ES 2133953T3 ES 96909153 T ES96909153 T ES 96909153T ES 96909153 T ES96909153 T ES 96909153T ES 2133953 T3 ES2133953 T3 ES 2133953T3
- Authority
- ES
- Spain
- Prior art keywords
- pct
- farnesyl
- date
- procedure
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical class C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 title 1
- 150000001637 borneol derivatives Chemical class 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 abstract 1
- 102000004243 Tubulin Human genes 0.000 abstract 1
- 108090000704 Tubulin Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000000986 microtubule polymerisation Effects 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
ESTERES DE BORNEOL DE FORMULA GENERAL (I), DONDE R{SUP,1} ES T 8}, C(O) CH(NR{SUP,7A}R{SUP,7B}) R{SUP,7B} SON IGUAL O DISTINTOS Y ES R{SUP,7}, R{SUP,7} ES HIDROGENO, A, -C(O)NHR{SUP,9D}, }, ALQUILO C{SUB,1} LES O DISTINTOS Y SON R{SUP,8}, R{SUP,8} ES (I), HETEROARILO SUSTITUIDO CON X{SUP,3}, ARALQUILO C{SUB,7} C{SUB,16}, ALQUILO, A ES B BIDORES DE LA PROTEINQUINASA O INHIBIDORES DE LA FARNESILPROTEINTRANSFERASA COMO, POR EJEMPLO, FARNESILO, (II) T ES UN ENLACE, Z{SUP,I} O UN GRUPO (III) QUE TIENEN LA CAPACIDAD DE INFLUIR EN LA POLIMERIZACION DE LA TUBULINA O EN LA DESPOLIMERIZACION DE LA TUBULINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19513040A DE19513040A1 (de) | 1995-03-29 | 1995-03-29 | Neue Borneolester, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2133953T3 true ES2133953T3 (es) | 1999-09-16 |
Family
ID=7759027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES96909153T Expired - Lifetime ES2133953T3 (es) | 1995-03-29 | 1996-03-29 | Esteres de borneol, procedimiento para su preparacion y su utilizacion farmaceutica. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5965609A (es) |
| EP (1) | EP0817769B1 (es) |
| JP (1) | JPH11503171A (es) |
| AT (1) | ATE180469T1 (es) |
| CA (1) | CA2216655A1 (es) |
| DE (2) | DE19513040A1 (es) |
| DK (1) | DK0817769T3 (es) |
| ES (1) | ES2133953T3 (es) |
| GR (1) | GR3030870T3 (es) |
| WO (1) | WO1996032376A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2212237A1 (en) * | 1997-09-05 | 1999-03-05 | John M. Webster | Novel antineoplastic agents |
| EP3308783B1 (en) | 2015-06-10 | 2021-03-03 | Jiangsu Simcere Pharmaceutical Co., Ltd | Edaravone and borneol for treating amyotrophic lateral sclerosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601676B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Procede de preparation du taxol et du desacetyl-10 taxol |
| US5248796A (en) * | 1992-06-18 | 1993-09-28 | Bristol-Myers Squibb Company | Taxol derivatives |
| DE4416374A1 (de) * | 1994-05-05 | 1995-11-09 | Schering Ag | Neue Borneolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
-
1995
- 1995-03-29 DE DE19513040A patent/DE19513040A1/de not_active Withdrawn
-
1996
- 1996-03-29 AT AT96909153T patent/ATE180469T1/de not_active IP Right Cessation
- 1996-03-29 DK DK96909153T patent/DK0817769T3/da active
- 1996-03-29 US US08/930,009 patent/US5965609A/en not_active Expired - Fee Related
- 1996-03-29 WO PCT/EP1996/001404 patent/WO1996032376A1/de not_active Ceased
- 1996-03-29 JP JP8530683A patent/JPH11503171A/ja not_active Ceased
- 1996-03-29 CA CA002216655A patent/CA2216655A1/en not_active Abandoned
- 1996-03-29 DE DE59602007T patent/DE59602007D1/de not_active Expired - Lifetime
- 1996-03-29 ES ES96909153T patent/ES2133953T3/es not_active Expired - Lifetime
- 1996-03-29 EP EP96909153A patent/EP0817769B1/de not_active Expired - Lifetime
-
1999
- 1999-07-27 GR GR990401956T patent/GR3030870T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0817769B1 (de) | 1999-05-26 |
| ATE180469T1 (de) | 1999-06-15 |
| CA2216655A1 (en) | 1996-10-17 |
| GR3030870T3 (en) | 1999-11-30 |
| JPH11503171A (ja) | 1999-03-23 |
| DE59602007D1 (de) | 1999-07-01 |
| US5965609A (en) | 1999-10-12 |
| WO1996032376A1 (de) | 1996-10-17 |
| EP0817769A1 (de) | 1998-01-14 |
| DK0817769T3 (da) | 1999-11-08 |
| DE19513040A1 (de) | 1996-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guse | Ca 2+ signaling in T-lymphocytes | |
| JP3494624B2 (ja) | 新規な環状テトラペプチド誘導体とその医薬用途 | |
| Hartung et al. | Recombinant interleukin-1β stimulates eicosanoid production in rat primary culture astrocytes | |
| HUP9901209A2 (hu) | Opioid analóg peptid vegyületek, eljárás előállításukra és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| ATE234857T1 (de) | Antithrombotische tripeptid-wirkstoffe | |
| AR003415A1 (es) | Compuestos analogos de lactacistina, metodo para inhibir la proteolisis dependiente de proteasoma, metodo para identificar un proceso biologico mediado por proteolisis dependiente de proteasoma, uso de dichos compuestos para preparar un medicamento para tratar una condicion mediada por proteolisis dependiente de proteasoma. | |
| MX9200240A (es) | Derivados de 1-2[amino-3,4-dioxo-1-ciclobuten-1il]amino]alquil]-acido, procedimiento para su preparacion y composicion farmaceutica que los contiene. | |
| WO2002068601A9 (en) | Small peptides capable of modulating the function of cd66 (ceacam) family members | |
| FR2804115B1 (fr) | Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant | |
| ES2011919A6 (es) | Metodo para producir compuestos antagonistas de los leucotrienos. | |
| IE812974L (en) | Tri-,tetra- and penta peptides | |
| Klein et al. | IL-4 regulates the morphology, cytoskeleton, and proliferation of human umbilical vein endothelial cells: relationship between vimentin and CD23 | |
| Peyron et al. | Phosphorylation of two cytosolic proteins. An early event of T-cell activation | |
| DE69424039D1 (de) | Neue verbindungen | |
| ES2133953T3 (es) | Esteres de borneol, procedimiento para su preparacion y su utilizacion farmaceutica. | |
| DK0553113T3 (da) | Adhæsionsreceptorer for patogene eller opportunistiske mikroorganismer | |
| FR2707089B1 (fr) | Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| Krueger | Somnogenic activity of muramyl peptides | |
| ES2287048T3 (es) | Inhbicion de la motilidad celular y la angiognesis mediante nhibidores del dominio gbr2sh2. | |
| AR031126A1 (es) | Acidos amino(oxo)aceticos inhibidores de la proteina tirosina fosfatasa | |
| Roark et al. | Synthesis and biological activity of modified peptide inhibitors of angiotensin-converting enzyme | |
| Oostendorp et al. | Suppression of lymphocyte proliferation by a retroviral p15E‐derived hexapeptide | |
| BG99313A (en) | 117-alkylketonesteroids as 5- -reductase inhibitors | |
| BR9612317A (pt) | Análogos nucleotìdeos. | |
| ES2023746A6 (es) | Procedimiento de preparacion de peptidos de serina-acido aspartico- lisina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 817769 Country of ref document: ES |